索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]符灵智,许剑峰,马彦卓,等.盐皮质激素受体拮抗剂的研究进展[J].国际心血管病杂志,2024,02:69-73.
点击复制

盐皮质激素受体拮抗剂的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
69-73
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
符灵智; 许剑峰; 马彦卓; 陈瑜; 杨茜; 齐书英
050082 石家庄，中国人民解放军联勤保障部队第九八〇医院心内科
Author(s):
-
关键词:
盐皮质激素受体拮抗剂; 非奈利酮; 依普利酮; 螺内酯
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.002
文献标识码:
-
摘要:
肾素-血管紧张素-醛固酮系统激活可以导致醛固酮产生，醛固酮结合盐皮质激素受体参与维持机体水和电解质平衡，盐皮质激素受体拮抗剂（MRA）是竞争性抑制醛固酮与盐皮质激素受体结合的药物，已被证明可以显著降低心脏疾病的风险及减缓肾脏疾病的进展。该文主要介绍各类MRA的作用机制、生理效应和不良反应。
Abstract:
-

参考文献/References

[1] Buonafine M, Bonnard B, Jaisser F. Mineralocorticoid receptor and cardiovascular disease[J]. Am J Hypertens, 2018, 31(11):1165-1174.
[2] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[J].N Engl J Med, 1999, 341(10):709-717.
[3] Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin Ⅱ suppression[J]. J Endocrinol, 1981, 91(3):457-465.
[4] Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension[J]. Am J Cardiol, 1993, 71(3):A12-A16.
[5] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[6] Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med, 2014, 370(15):1383-1392.
[7] Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study[J]. J Am Coll Cardiol, 2012, 59(18):1598-1603.
[8] Ferreira JP, Lamiral Z, McMurray JJV, et al. Impact of insulin treatment on the effect of eplerenone: insights from the EMPHASIS-HF trial[J]. Circ Heart Fail, 2021, 14(6):e008075.
[9] Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans[J]. Drug Metab Dispos, 2003, 31(11):1448-1455.
[10] Weinberger MH, Roniker B, Krause SL,et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension[J]. Am J Hypertens, 2002, 15(8):709-716.
[11] Ito S, Itoh H, Rakugi H, et al. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction[J]. Hypertens Res, 2021, 44(5):489-497.
[12] Ito S, Itoh H, Rakugi H, et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study[J]. J Hum Hypertens, 2019, 33(7):542-551.
[13] Ito S, Itoh H, Rakugi H, et al. Double-Blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)[J]. Hypertension, 2020, 75(1):51-58.
[14] Yamada M, Mendell J, Takakusa H, et al. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans[J]. Drug Metab Dispos, 2019, 47(3):340-349.
[15] Iijima T, Katoh M, Takedomi K, et al. Discovery of apararenone(MT-3995)as a highly selective, potent, and novel nonsteroidal mineralocorticoid receptor antagonist[J]. J Med Chem, 2022, 65(12):8127-8143.
[16] Wada TKH, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study[J]. Clin Exp Nephrol, 2021, 25(2):120-130.
[17] Bamberg K, William-Olsson L, Johansson U, et al. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone[J]. J Renin Angiotensin Aldosterone Syst, 2019, 20(1):1470320319827449.
[18] Bamberg K, Johansson U, Edman K, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion[J]. PLoS One, 2018, 13(2):e0193380.
[19] Erlandsson F, Albayaty M, Chialda L, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator[J]. Br J Clin Pharmacol, 2018, 84(7):1486-1493.
[20] Jaisser F, Tan X, Chi S, et al. The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury[J]. Front Pharmacol 2021, 12:604928.
[21] Bakris G, Pergola PE, Delgado B, et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study[J]. Hypertension, 2021, 78(1):74-81.
[22] Bakris G, Yang YF, Pitt B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial[J]. Hypertension, 2020, 76(1):144-149.
[23] Luettges KBM, Diemer JN. Finerenone reduces renal RORγt γδ T cells and protects against cardiorenal damage[J]. Am J Nephrol, 2022, 53(7):552-564.
[24] Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity[J]. Hypertension, 2018, 71(4):599-608.
[25] Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes[J]. Circulation, 2021, 143(6):540-552.
[26] Rico-Mesa JS, White A, Ahmadian-Tehrani A, et al. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone[J]. Curr Cardiol Rep, 2020, 22(11):140.
[27] Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial[J]. Am J Nephrol, 2019, 50(5):333-344.
[28] Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020, 383(23):2219-2229.
[29] Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial[J]. Am J Nephrol, 2019, 50(5):345-356.
[30] Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med, 2021, 385(24):2252-2263.

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究重点课题（20210200）
通信作者：齐书英， E-mail：qsy304@126.com
更新日期/Last Update: 2024-03-25